Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RAP-219

Phase 3Small molecule

RRapport Therapeutics Inc.

RAP-219 is one of 34 small molecule programs targeting Focal Seizure. It is currently in Phase 3.

3

Indications

5

Total Trials

4

Active Trials

33

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal SeizureRecruiting

Bipolar 1 DisorderActive, not recruiting

SeizureRecruiting

Focal SeizurePhase 3

Recruiting

Bipolar 1 DisorderPhase 2

Active, not recruiting

SeizurePhase 2

Recruiting

Competition

Competitive Landscape

33 competitors in Seizure

#DrugCompanyPhaseTrials

Keppra

Vimpat

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Epidiolex

Jazz Pharmaceuticals

Tegretol

Trileptal

Fycompa

CCatalyst Biosciences

Zonegran

AAzurity Pharmaceuticals

Topamax

Lamictal

GGlaxo Dba Glaxosmithkline

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Bipolar 1 Disorder

NCT07046494

Q1 2028

Phase 2Recruiting

Seizure

NCT07219407

Q3 2029

Phase 3Recruiting

Focal Seizure

NCT07594119

Phase 3Recruiting

Focal Seizure

NCT07563881

Clinical

Trials by Indication[1]

Focal Seizure2 trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Recruiting·RRapport Therapeutics Inc.·Phase 3·NCT07594119·312 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Recruiting·RRapport Therapeutics Inc.·Phase 3·NCT07563881·333 enrolled

Seizure1 trial

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Recruiting·RRapport Therapeutics Inc.·Phase 2·NCT07219407·30 enrolled

Epilepsy1 trial

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Completed·RRapport Therapeutics Inc.·Phase 2·NCT06377930·30 enrolled

Bipolar 1 Disorder1 trial

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

Active, not recruiting·RRapport Therapeutics Inc.·Phase 2·NCT07046494·253 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for RAP-219. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RAP-219 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RAP-219. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rapport Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRapport Therapeutics Inc.

Related News